Skip to contentHome page Seeking Alpha - Power to InvestorsTranscriptsOct 23, 2026, 7:17 PM ETAardvark Therapeutics, Inc. (AARD) StockSA Transcripts162.58K FollowersAardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials October 23, 2026 8:00 AM EDTCompany ParticipantsTien-Li Lee - CEO, Secretary & ChairmanManasi Jaiman - Chief Medical OfficerLynne BirdConference Call ParticipantsJoshua Schimmer - Cantor Fitzgerald & Co., Research DivisionChristopher Raymond - Raymond James & Associates, Inc., Research DivisionLeland Gershell - Oppenheimer & Co. Inc., Research DivisionCatherine Novack - JonesTrading Institutional Services, LLC, Research DivisionTazeen Ahmad - BofA Securities, Research DivisionBrian Abrahams - RBC Capital Markets, Research DivisionKelsey Lucerne - William Blair & Company L.L.C., Research DivisionMichael Ulz - Morgan Stanley, Research DivisionWilliam Wood - B. Riley Securities, Inc., Research DivisionRaghuram Selvaraju - H.C. Wainwright & Co, LLC, Research DivisionPresentationOperatorGood day. Thank you for standing by. Welcome to the Aardvark Therapeutics Update Call. [Operator Instructions] Please advise that today's conference will be recorded. With that, I'll now turn the call over to Aardvark Therapeutics' Founder, Chief Executive Officer, Tien-Li. Dr. Lee, please go ahead.Tien-Li LeeCEO, Secretary & ChairmanGood morning, everyone, and thank you for joining us today to review the efficacy and safety data from HERO, our Phase III trial of ARD-101 for the treatment of hyperphagia in patients with Prader-Willi syndrome and from its open-label extension. We will also share an update on the list of FDA clinical hold. As a reminder, both studies were stopped early before reaching their plan enrollment in duration, so the efficacy results should be viewed as exploratory. Joining me on the call are Dr. Manasi Jaiman, our Chief Medical Officer; and Dr. Lynne Bird of Rady Children's Hospital at UC San Diego, who served as an investigator on the HERO trial. Manasi will walk through the HERO and open-label extension data and then moderate a fireside chat with Dr. Bird on her clinical experience with ARD-101 and the needsRead more current AARD analysis and newsView all earnings call transcriptsCommentsTo ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.Is this happening to you frequently? Please report it on our feedback forum.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.